0.11%
1
0.11% 0.04% 18.20% 10.37% 5.69% 4.05% 30.43% 15.85% DMSO Erlotinib, 10µM MP470, 10µM Erlotinib,10µM + MP470,10µM C oncentration ( M) 0.1 1 10 P ercentS urvival 0 20 40 60 80 100 120 LN C aP D U 145 PC -3 0 2 4 6 8 10 12 14 16 18 Tarceva M P 470 Tarceva (10 µM ) + M P 470 [ IC 50]uM 1 uM 2 uM 5 uM 10 uM Apoptosis (% ) 0 10 20 30 40 50 DMSO Erlotinib M P470 Erlotinib+MP470 DMSO Erlotinib MP470 Imatinib E rl.+MP470 Erl.+Ima. 10M PARP Cleaved PARP -actin A B C D E
-
Upload
tucker-lee -
Category
Documents
-
view
16 -
download
0
description
A. B. C. D. E. Erl.+MP470. Erl.+Ima. Erlotinib. Imatinib. 0.04%. 5.69%. MP470. 10 M. DMSO. 0.11%. 4.05%. PARP. DMSO. Erlotinib, 10 µM. Cleaved PARP. 18.20%. 30.43%. -actin. 10.37%. 15.85%. MP470, 10 µM. Erlotinib,10 µM + MP470,10µM. - PowerPoint PPT Presentation
Transcript of 0.11%
0.11%
0.04%
18.20%
10.37%
5.69%
4.05%
30.43%
15.85%
DMSO Erlotinib, 10µM
MP470, 10µM Erlotinib,10µM + MP470,10µM
Concentration (M)
0.1 1 10
Per
cent
Su
rviv
al
0
20
40
60
80
100
120
LNCaPDU145PC-3
0
2
4
6
8
10
12
14
16
18
Tarceva MP470 Tarceva (10 µM)+ MP470
[IC50
] u
M
1 uM 2 uM 5 uM 10 uM
Ap
op
tosi
s (%
)
0
10
20
30
40
50
DMSOErlotinibMP470Erlotinib+MP470
DM
SO
Erlo
tinib
MP47
0Im
atin
ib
Erl.+M
P470
Erl.+I
ma.
10M
PARP
Cleaved PARP
-actin
A B C
D E
